Vera Therapeutics Struggles Continue with Downgrades from Analysts
Vera Therapeutics, a biotechnology company based in the United States, has received downgrades from analysts at Wedbush and Jefferies. These decisions may be due to the company’s ongoing struggles, including negative earnings per share (EPS) for the trailing 12 months (ttm) of -2.95 and poor performance in recent months and years.
Wedbush lowered their rating from “Outperform” to “Neutral” and reduced the price target from $33 to $8. Jefferies also downgraded their rating from “Buy” to “Hold” and decreased the price target from $32 to $6.
Past week: -66.28%
Past month: -60.37%
Past quarter: -70.89%
Past half year: -53.86%
Past year: -76.98%
Despite having sufficient current assets to cover short-term liabilities, as indicated by a cash per share of 4.12 and a current ratio of 7.90, Vera Therapeutics does not pay dividends and it is unclear whether the company is profitable. The company’s gross margin and operating margin, which are measures of profitability, are not provided.
Price-to-book ratio (P/B): 1.66
Price-to-sales ratio (P/S): Not provided
52-week range: 12.28 to 29.20
Beta: – (potentially lower volatility compared to the overall market)
Earning growth for current year: 41.20%
Earning growth for next year: -16.40%
Earnings per share for next quarter: -0.87
Earnings per share for next 5 years: –
Earnings per share for past 5 years: Not provided
Return on assets (ROA): -55.60%
Return on equity (ROE): -68.10%
Vera Therapeutics has 41 employees and its stock is shortable and optionable. The company’s debt-to-equity ratio and long-term debt-to-equity ratio are both 0.05, indicating a low level of debt relative to equity. The company’s quick ratio, which is a measure of a company’s ability to pay off its short-term liabilities using its most liquid assets, is 7.90.
The company’s relative strength index (RSI), which is a technical indicator used to measure the strength of a stock’s price action, is currently at 18.39. An RSI below 30 is often considered oversold, while an RSI above 70 is considered overbought.
It remains to be seen how Vera Therapeutics will address its negative earnings and poor performance in the future. The company’s earning growth for the current year and the next year is predicted to be 41.20% and -16.40%, respectively. The company’s earnings per share for the next quarter and next 5 years are forecast to be -0.87 and -, respectively. The company’s earnings per share for the past 5 years is not provided.
Roy Frigo an avid economist and an expert on global politics and economic pressures that can affect market conditions. He has a Masters Degree in Economics from Westminster University with previous roles including Investment Banking.
Email: [email protected]analystsbuzz.com
Address: 1316 Stephens Town Road, Linden, TN 37096 USA
Zip code: 37096